Search Result

Isoforms Recommended:	JNK3

Results for "

JNK3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (2) CDK (1) Cytochrome P450 (1) Discoidin Domain Receptor (1) Ferroptosis (1) GSK-3 (2) JNK (29) p38 MAPK (3)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Inflammation/Immunology (5) Neurological Disease (10)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149268

JNK3 inhibitor-6	JNK	Neurological Disease
JNK3 inhibitor-6 (Compound A53) is a selective *JNK3* Inhibitor (IC₅₀=78 nM). JNK3 inhibitor-6 has neuroprotective effect, and can used for research of neurodegenerative diseases .

HY-139624

JNK3 inhibitor-1

JNK Others

JNK3 inhibitor-1 is a potent and selective JNK3 inhibitor (IC₅₀ = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.

JNK3 inhibitor-1	JNK	Others
JNK3 inhibitor-1 is a potent and selective *JNK3* inhibitor (IC₅₀ = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.

HY-149279

JNK3 inhibitor-7	JNK	Neurological Disease
JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier *JNK3* inhibitor with IC₅₀ values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-7 shows significant neuroprotective effects. JNK3 inhibitor-7 has the potential for the research of Alzheimer’s disease (AD) .

HY-149280

JNK3 inhibitor-8	JNK	Neurological Disease
JNK3 inhibitor-8 is a potent, delective, orally active and cross the blood-brain barrier *JNK3* inhibitor with IC₅₀ values of 21, 2203, >10000 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-8 shows significant neuroprotective effects. JNK3 inhibitor-8 has the potential for the research of Alzheimer’s disease (AD) .

HY-150552

JNK3 inhibitor-2	JNK Discoidin Domain Receptor	Inflammation/Immunology Cancer
JNK3 inhibitor-2 is a potent and selective *JNK3* inhibitor with IC₅₀ values of >100, >100, 0.25 µM for JNK1, JNK2, JNK3, respectively. JNK3 inhibitor-2 shows DDR1 and EGFR (T790M, L858R) inhibition .

HY-151928

JNK3 inhibitor-3	JNK	Neurological Disease
JNK3 inhibitor-3 (compound 15g) is a selective, BBB permeable and orally active c-Jun N-terminal kinase 3 (JNK3) inhibitor. JNK3 inhibitor-3 has inhibitory activities to JNK1, JNK2 and JNK3 with IC₅₀ values of 147.8, 44.0 and 4.1 nM, respectively. JNK3 inhibitor-3 significantly improves the memory in mouse dementia model. JNK3 inhibitor-3 can be used for the research of Alzheimer’s disease .

HY-151962

JNK3 inhibitor-5	JNK Apoptosis GSK-3 p38 MAPK	Neurological Disease
JNK3 inhibitor-5 (Compound 22b) is a potent and selective *JNK3* inhibitor with an IC₅₀ of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .

HY-151929

JNK3 inhibitor-4	JNK	Neurological Disease
JNK3 inhibitor-4 is a potent inhibitor of *JNK3* (IC₅₀=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms *JNK1* (IC₅₀=143.9 nM) and *JNK2* (IC₅₀=298.2 nM) . JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability .

HY-117248

SR-3737

JNK p38 MAPK Neurological Disease

SR-3737 is a JNK3 and p38 inhibitor (IC₅₀: 12 and 3 nM) .
HY-77009

JNK-IN-13

JNK Cancer

JNK-IN-13 (compound 1) is a potent and selective JNK inhibitor with IC₅₀s of 290 nM and 500 nM for JNK3 and JNK2, respectively .

SR-3737	JNK p38 MAPK	Neurological Disease
SR-3737 is a *JNK3* and p38 inhibitor (IC₅₀: 12 and 3 nM) .

JNK-IN-13	JNK	Cancer
JNK-IN-13 (compound 1) is a potent and selective *JNK* inhibitor with IC₅₀s of 290 nM and 500 nM for JNK3 and JNK2, respectively .

HY-107600

IQ-3 1 Publications Verification	JNK	Inflammation/Immunology
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .

HY-107596

SR-3576

JNK Others

SR-3576 is a highly potent and selective JNK3 inhibitor with an IC₅₀ of 7 nM .

SR-3576	JNK	Others
SR-3576 is a highly potent and selective *JNK3* inhibitor with an IC₅₀ of 7 nM .

HY-14761

Bentamapimod 5+ Cited Publications AS 602801	JNK	Cancer
Bentamapimod (AS 602801) is an ATP-competitive *JNK* inhibitor with IC₅₀ of 80 nM, 90 nM, and 230 nM for *JNK1, JNK2, and JNK3*, respectively.

HY-15617

JNK-IN-7

4 Publications Verification

JNK inhibitor
JNK Cancer

JNK-IN-7 is a potent JNK inhibitor with IC₅₀ of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.

JNK-IN-7 4 Publications Verification JNK inhibitor	JNK	Cancer
JNK-IN-7 is a potent *JNK* inhibitor with IC₅₀ of 1.5, 2 and 0.7 nM for *JNK1, JNK2* and *JNK3*, respectively.

HY-15881

*TCS JNK* 5a** 1 Publications Verification JNK Inhibitor IX	JNK Apoptosis	Cancer
TCS JNK 5a is a potent *JNK3* inhibitor with a pIC₅₀ of 6.7. TCS JNK 5a also inhibits *JNK2* with a pIC₅₀ of 6.5.

HY-13319

JNK-IN-8 30+ Cited Publications JNK Inhibitor XVI	JNK	Cancer
JNK-IN-8 (JNK Inhibitor XVI) is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively .

HY-P2246

JTP10-△-TATi TFA

JNK Cancer

JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
HY-P2247

JTP10-△-R9 TFA

JNK Cancer

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

JTP10-△-TATi TFA	JNK	Cancer
JTP10-△-TATi TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

JTP10-△-R9 TFA	JNK	Cancer
JTP10-△-R9 TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

HY-N7394A

(-)-Zuonin A 1 Publications Verification D-Epigalbacin	JNK	Cancer
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective *JNKs* inhibitor, with IC₅₀s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .

HY-150053

JNK-IN-11	JNK	Neurological Disease
JNK-IN-11 (compound 1) is a potent *JNK* inhibitor with an IC₅₀ value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .

HY-12041

SP600125 Maximum Cited Publications 405 Publications Verification	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 is an orally active, reversible, and ATP-competitive *JNK* inhibitor with IC₅₀s of 40, 40 and 90 nM for *JNK1, JNK2* and *JNK3, respectively. SP600125 is a potent ferroptosis* inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis ^[3].

HY-149930

YL5084	JNK Apoptosis	Cancer
YL5084, a covalent *JNK* inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC₅₀s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner .

HY-155593

JNK-1-IN-2	JNK	Inflammation/Immunology
JNK-1-IN-2 (Compound c6) is a *JNK-1* inhibitor (IC₅₀: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC₅₀s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis .

HY-125838

J30-8	JNK	Neurological Disease
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC₅₀ of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases .

HY-100233

IQ-1S free acid 1 Publications Verification	JNK	Inflammation/Immunology Cancer
IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC₅₀ of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three *JNKs with K_ds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2*, respectively.

HY-13319G

JNK-IN-8 JNK Inhibitor XVI	JNK	Cancer
JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively .

HY-150688

JAK3-IN-13	JNK	Cancer
JAK3-IN-13 is a potent, selective and orally active *JAK3* inhibitor with IC₅₀ values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .

HY-156182

JNK-IN-14	JNK Cytochrome P450	Cancer
JNK-IN-14 is a potent *JNK* inhibitor with IC₅₀ values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis. JNK-IN-14 shows cell population arrest at the G2/M phase and slightly inhibits beclin-1 production at K562 leukemia cells relative to SP600125 (HY-12041), showing higher inhibitory ability.

HY-139254

Indirubin-3′-oxime IDR3O; I3O	CDK GSK-3 JNK	Neurological Disease
Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β *(GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK* (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes ^[3].

HY-100115

TA-02 2 Publications Verification	p38 MAPK Autophagy	Cardiovascular Disease Inflammation/Immunology Cancer
TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC₅₀ of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) .

Cat. No.	Product Name	Type

HY-13319G

JNK-IN-8 (GMP) JNK Inhibitor XVI (GMP)	Fluorescent Dye
JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively .

Cat. No.	Product Name	Type

HY-13319G

JNK-IN-8 (GMP) JNK Inhibitor XVI (GMP)	Biochemical Assay Reagents
JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P2246

JTP10-△-TATi TFA

JNK Cancer

JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
HY-P2247

JTP10-△-R9 TFA

JNK Cancer

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

JTP10-△-TATi TFA	JNK	Cancer
JTP10-△-TATi TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

JTP10-△-R9 TFA	JNK	Cancer
JTP10-△-R9 TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .

(-)-Zuonin A 1 Publications Verification D-Epigalbacin	Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill. Cancer	JNK
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective *JNKs* inhibitor, with IC₅₀s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701790

	JNK3 Protein, Human MAPK10; Mitogen-activated protein kinase 10; MAP kinase 10; MAPK 10; MAP kinase p49 3F12; Stress-activated protein kinase 1b; SAPK1b; Stress-activated protein kinase JNK3; c-Jun N-terminal kinase 3	Human	E. coli
	JNK3 is a critical serine/threonine protein kinase in neuronal processes, regulating proliferation, differentiation, migration, and apoptosis. Activation through MAP2K4/MKK4 and MAP2K7/MKK7 leads to phosphorylation of JNK3, which in turn phosphorylates AP-1 components such as JUN and ATF2, thereby regulating AP-1 transcriptional activity. JNK3 Protein, Human is the recombinant human-derived JNK3 protein, expressed by E. coli , with tag free. The total length of JNK3 Protein, Human is 423 a.a., .

HY-P701791

	JNK3 Protein, Human (His) MAPK10; Mitogen-activated protein kinase 10; MAP kinase 10; MAPK 10; MAP kinase p49 3F12; Stress-activated protein kinase 1b; SAPK1b; Stress-activated protein kinase JNK3; c-Jun N-terminal kinase 3	Human	E. coli
	JNK3 is a critical serine/threonine protein kinase in neuronal processes, regulating proliferation, differentiation, migration, and apoptosis. Activation through MAP2K4/MKK4 and MAP2K7/MKK7 leads to phosphorylation of JNK3, which in turn phosphorylates AP-1 components such as JUN and ATF2, thereby regulating AP-1 transcriptional activity. JNK3 Protein, Human (His) is the recombinant human-derived JNK3 protein, expressed by E. coli , with N-6*His labeled tag. The total length of JNK3 Protein, Human (His) is 423 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P80198

JNK1+JNK3 Antibody	WB, IP	Mouse, Rat
JNK1+JNK3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48/53 kDa, targeting to JNK1+JNK3. It can be used for WB,IP assays with tag free, in the background of Mouse, Rat.

HY-P80197

JNK1+JNK2+JNK3 Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
JNK1+JNK2+JNK3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48/53 kDa, targeting to JNK1+JNK2+JNK3. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P83405

JNK3 Antibody (YA3150) Mitogen-activated protein kinase 10; MAP kinase 10; MAPK 10; MAP kinase p49 3F12; Stress-activated protein kinase 1b; SAPK1b; MAPK10; JNK3; JNK3A; PRKM10; SAPK1B	WB, ICC/IF, FC	Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

JNK3

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products